

ARCUS OVERVIEW

NYSE: RCUS



Global, clinical-stage biopharmaceutical company at the forefront of designing novel combination therapies for cancer

HIGHLY PRODUCTIVE DRUG DISCOVERY

Small Molecules & Antibodies Designed to Be Combined



Targets: CD73, HIF2a, A2a/2b, AXL



Targets: TIGIT, PD-1, CD39

Goal of 1-2
new molecules advancing into clinic each year



Accelerated
P 1/2 signal-seeking & platform studies

DIVERSE PIPELINE WITH MULTIPLE "SHOTS ON GOAL"

7



Different molecules in clinic

4



Registrational Phase 3 trials evaluating a differentiated, Fc-silent anti-TIGIT antibody domvanalimab

24-36



Months for potential approval & revenue generation

\$10B+



Addressable market opportunity in the U.S. based on expected drug treatable patient population

TOP-TIER PARTNERS FOR STRATEGIC & CLINICAL COLLABORATIONS



Funding:

~\$1.4B

- Holds ~19% equity stake in Arcus
- 50/50 Cost-sharing for optioned programs
- Co-development / co-commercialization in the U.S.



STRONG FINANCIAL POSITION & CASH RUNWAY WITH FUNDING INTO 2026



~\$950M cash, cash equivalent & marketable securities as of 9/30/2023

HQ & RESEARCH CAMPUSES IN BAY AREA



~600 employees

Learn more at investors.arcusbio.com

This summary is provided as of 9/30/23. For a more complete description of our business and risks and uncertainties that may affect forward-looking statements made in this summary, including the statement regarding funding into 2026, please refer to our full corporate presentation and latest Form 10-K and Form 10-Q, which can be found at investors.arcusbio.com.